New stem cell approach aims to treat tough anemia cases
NCT ID NCT05757310
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new way to do a stem cell transplant for people with severe aplastic anemia whose disease has come back or not improved with standard treatments. The approach uses a milder conditioning regimen and removes certain immune cells from the donor cells to reduce side effects. The study will enroll 6 participants to see if the procedure is safe and feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cell transplant with drugs to suppress the immune system (cyclophosphamide, pentostatin, anti-thymocyte globulin)
- What this could lead to
- If this works, it could offer a new treatment option for people with severe aplastic anemia who have not responded to standard therapy.
- What could go wrong
- This is a very early, small phase 1 trial with only 6 participants. The main goal is safety, not effectiveness. There are risks of infection, graft-versus-host disease, and other serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States